OmniAb (NASDAQ:OABI) Hits New 52-Week High – Should You Buy?

Posted by Brian Himes on Aug 26th, 2026

OmniAb, Inc. (NASDAQ:OABI – Get Free Report)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $4.65 and last traded at $4.6840, with a volume of 1415824 shares trading hands. The stock had previously closed at $4.33.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Weiss Ratings upgraded OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a research report on Monday, August 17th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, OmniAb currently has an average rating of “Hold” and an average price target of $11.00.

Read Our Latest Stock Report on OABI

OmniAb Stock Down 1.1%

The firm has a market cap of $674.67 million, a price-to-earnings ratio of -12.94 and a beta of 0.45. The company’s 50-day moving average price is $2.63 and its 200-day moving average price is $2.13.

OmniAb (NASDAQ:OABI – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.07. OmniAb had a negative net margin of 115.12% and a negative return on equity of 16.59%. The firm had revenue of $13.41 million during the quarter, compared to the consensus estimate of $4.69 million. Analysts predict that OmniAb, Inc. will post -0.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OmniAb

Several hedge funds and other institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its position in shares of OmniAb by 20.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 44,809 shares of the company’s stock worth $78,000 after purchasing an additional 7,624 shares during the last quarter. Rhumbline Advisers raised its holdings in OmniAb by 6.0% in the 2nd quarter. Rhumbline Advisers now owns 160,728 shares of the company’s stock valued at $280,000 after buying an additional 9,163 shares during the period. Osaic Holdings Inc. lifted its position in OmniAb by 214.4% in the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after buying an additional 9,716 shares during the last quarter. AQR Capital Management LLC acquired a new position in OmniAb in the first quarter valued at about $25,000. Finally, BNP Paribas Financial Markets boosted its stake in OmniAb by 92.5% during the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock worth $35,000 after buying an additional 10,438 shares during the period. Hedge funds and other institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

(Get Free Report)

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.